title: The effect of HIV infection on atherosclerosis and lipoprotein metabolism: a one year prospective study.
abstract: OBJECTIVE
  HIV infection is associated with dyslipidaemia and increased risk of cardiovascular disease. The effects of HIV infection and antiretroviral treatment on surrogate markers of atherosclerosis, and lipoprotein metabolism were evaluated in a 12 month prospective study.
  
  
  RESULTS
  Treatment-naive HIV patients were recruited into one of three groups: untreated HIV infection not likely to require initiation of antiretroviral therapy (ART) for at least 12 months; initiating treatment with non nucleoside reverse transcriptase inhibitor-containing ART regimen and initiating treatment with protease inhibitor-containing ART regimen. The patients underwent assessment of carotid intima-media thickness (cIMT), pulse wave velocity (PWV), brachial flow-mediated dilation (FMD) and variables of plasma lipoprotein metabolism at baseline and 12 months. The findings were compared with published values for age and sex matched HIV-negative healthy subjects in a cross-sectional fashion. cIMT and FMD were lower while PWV was higher in HIV-patients compared with HIV-negative individuals; none of the markers changed significantly during 12 months follow up. HIV patients had hypoalphalipoproteinemia and elevated plasma levels of lecithin:cholesterol acyltransferase (LCAT) and cholesteryl ester transfer protein. The only significant changes in lipid-related variables were elevation of total cholesterol and triglycerides in patients treated with PI-containing regimen and elevation of plasma LCAT levels in patients treated with NNRTI-containing regimen. The ability of whole and apoB-depleted plasma to effect cholesterol efflux was not impaired in all three groups.
  
  
  CONCLUSIONS
  This study did not find evidence for rapid progression of subclinical atherosclerosis and deterioration of dyslipidaemia in HIV patients within 1 year.
authors: Baker Heart and Diabetes Institute, Melbourne, Australia.
authors: Honor
authors: H
authors: Rose
authors: Hann
authors: H
authors: Low
authors: Elizabeth
authors: E
authors: Dewar
authors: Michael
authors: M
authors: Bukrinsky
authors: Jennifer
authors: J
authors: Hoy
authors: Anthony
authors: A
authors: Dart
authors: Dmitri
authors: D
authors: Sviridov
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use; D016632:Apolipoprotein A-I / Q000097:blood; D050197:Atherosclerosis / Q000453:epidemiology* / Q000378:metabolism; D002784:Cholesterol / Q000097:blood; D050171:Dyslipidemias / Q000453:epidemiology* / Q000378:metabolism; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000453:epidemiology* / Q000378:metabolism; D006801:Humans; D008074:Lipoproteins / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012307:Risk Factors; D014280:Triglycerides / Q000097:blood
chemical_list: D019380:Anti-HIV Agents; D016632:Apolipoprotein A-I; D008074:Lipoproteins; D014280:Triglycerides; D002784:Cholesterol
references: Pediatr Infect Dis J. 2010 Jul;29(7):634-8
references: 20589981
references: Atherosclerosis. 2008 Jul;199(1):79-86
references: 18054941
references: Atherosclerosis. 2009 Jun;204(2):418-23
references: 18990393
references: J Am Coll Cardiol. 2012 May 22;59(21):1891-6
references: 22595409
references: Circulation. 2004 Apr 6;109(13):1603-8
references: 15023877
references: J Am Coll Cardiol. 2002 Aug 21;40(4):773-9
references: 12204510
references: Clin Sci (Lond). 1998 Dec;95(6):669-79
references: 9831691
references: Antivir Ther. 2008;13(2):177-87
references: 18505169
references: Int J Cardiovasc Imaging. 2012 Apr;28(4):935-41
references: 21643942
references: Mol Pharmacol. 2005 Sep;68(3):690-700
references: 15976036
references: Am J Cardiol. 2012 Mar 1;109(5):742-7
references: 22169125
references: Atherosclerosis. 2007 Jun;192(2):407-12
references: 16787645
references: PLoS Biol. 2006 Oct;4(11):e365
references: 17076584
references: Atherosclerosis. 2006 Apr;185(2):361-7
references: 16137695
references: Am Heart J. 2006 Jun;151(6):1147-55
references: 16781213
references: Circulation. 1999 Aug 17;100(7):700-5
references: 10449690
references: Am Heart J. 2004 Jan;147(1):55-9
references: 14691419
references: PLoS Med. 2007 Jan;4(1):e43
references: 17411317
references: AIDS. 2009 Sep 10;23(14):1841-9
references: 19455012
references: Atherosclerosis. 2012 Dec;225(2):408-11
references: 23089369
references: J Clin Invest. 2003 Feb;111(3):389-97
references: 12569165
references: J Am Coll Cardiol. 2006 Mar 21;47(6):1117-23
references: 16545639
references: J Acquir Immune Defic Syndr. 2010 Jul;54(3):275-84
references: 20658749
references: Atherosclerosis. 2008 Feb;196(2):720-6
references: 17275008
references: HIV Med. 2005 Nov;6(6):380-7
references: 16268819
references: AIDS. 2010 Mar 27;24(6):885-90
references: 19952712
references: Lancet. 2012 Jun 2;379(9831):2053-62
references: 22541275
references: Eur Heart J. 2012 Mar;33(5):657-65
references: 21498847
references: Atherosclerosis. 2009 Jun;204(2):586-9
references: 19084229
references: AIDS. 2007 May 31;21(9):1137-45
references: 17502724
references: AIDS. 2005 Jun 10;19(9):927-33
references: 15905673
references: Curr HIV/AIDS Rep. 2005 Jun;2(2):68-73
references: 16091251
references: J Acquir Immune Defic Syndr. 2011 Oct 1;58(2):148-53
references: 21792061